250
Participants
Start Date
August 25, 2023
Primary Completion Date
June 30, 2027
Study Completion Date
July 20, 2027
PTC518
PTC518 will be administered per dose and schedule specified in the arm.
Westmead Hospital, Westmead
Monash Health, Clayton
Medical University Innsbruck, Innsbruck
University of Otago, New Zealand Brain Research Institute, Christchurch
Hospital de la Santa Creu I Sant Pau, Barcelona
Charite University Medicine Berlin, Berlin
Hôpital Universitaire de Marseille Hôpital de la Timone, Marseille
IRCCS Carlo Besta Neurological Institutte, Milan
Hospital Ramón y Cajal, Madrid
Irccs Istituto Delle Scienze Neurologiche Di Bologna Uoc Clinica Neurologica, Bologna
Ruhr-Univ. Bochum St. Joseph-Hospital, Bochum
George-Huntington-Institut, Münster
Hospital Universitario Cruces, Barakaldo
Centre Hospitalier Universitaire d'Angers, Angers
IRCCS Casa Sollievo della Sofferenza Research Hospital, San Giovanni Rotondo
Brain and Spine institute Paris, Paris
Ulm University, UKU, Dep. of Neurology, Ulm
Hospital Universitario Burgos, Burgos
The Ottawa Hospital, Parkinson's and Movement Disorders Clinic, Ottawa
Leiden University Medical Center, Leiden
The Barbery National Centre for Mental Health, Birmingham
University Hospital of Wales, Cardiff
UCL Queen Square Institute of Neurology National Hospital for Neurology and Neurosurgery, London
Manchester University NHS Foundation Trust, Manchester
Lead Sponsor
PTC Therapeutics
INDUSTRY